Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is -10.09% lower on its value in year-to-date trading and has touched a low of $103.63 and a high of $157.98 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NBIX stock was last observed hovering at around $118.35 in the last trading session, with the day’s gains setting it 0.11%.
Currently trading at $118.46, the stock is 2.95% and -6.72% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.73 million and changing 0.09% at the moment leaves the stock -12.58% off its SMA200. NBIX registered 3.74% gain for a year compared to 6-month loss of -10.62%. The firm has a 50-day simple moving average (SMA 50) of $126.9914 and a 200-day simple moving average (SMA200) of $135.5026.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -1.16% gain in the last 1 month and extending the period to 3 months gives it a -18.69%, and is 5.38% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.11% over the week and 1.99% over the month.
Neurocrine Biosciences, Inc. (NBIX) has around 1400 employees, a market worth around $11.96B and $2.12B in sales. Current P/E ratio is 35.79 and Fwd P/E is 17.40. Profit margin for the company is 16.00%. Distance from 52-week low is 14.31% and -25.02% from its 52-week high. The company has generated returns on investments over the last 12 months (12.27%).
The EPS is expected to grow by 93.28% this year
889.0 institutions hold shares in Neurocrine Biosciences, Inc. (NBIX), with institutional investors hold 97.12% of the company’s shares. The shares outstanding are 100.98M, and float is at 98.78M with Short Float at 2.48%. Institutions hold 96.17% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.19 million shares valued at $1.95 billion. The investor’s holdings represent 14.2191 of the NBIX Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 10.06 million shares valued at $1.38 billion to account for 10.0766 of the shares outstanding. The other top investors are STATE STREET CORP which holds 4.61 million shares representing 4.6176 and valued at over $634.43 million, while RENAISSANCE TECHNOLOGIES LLC holds 2.4731 of the shares totaling 2.47 million with a market value of $339.79 million.
Neurocrine Biosciences, Inc. (NBIX) Insider Activity
The most recent transaction is an insider sale by Boyer David W., the company’s Chief Corp. Affairs Officer. SEC filings show that Boyer David W. sold 3,461 shares of the company’s common stock on Sep 13 ’24 at a price of $121.88 per share for a total of $0.42 million. Following the sale, the insider now owns 1672.0 shares.
Still, SEC filings show that on Aug 15 ’24, RASTETTER WILLIAM H (Director) disposed off 14,250 shares at an average price of $146.69 for $2.09 million. The insider now directly holds 37,491 shares of Neurocrine Biosciences, Inc. (NBIX).
